In a large, international study involving patients with T2DM from the Asia Pacific, the Middle East, and North America, the use of SGLT2 inhibitors decreased cardiovascular events in a broad evaluation of patient outcomes and characteristics.39 Here, SLC5A2 is linked to type 2 diabetes mellitus.